Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2007

View Archived Issues

Gilead Sciences reports progress of first quarter

Phase III studies show efficacy and safety of ferumoxytol iron replacement therapy

Recent GSK patent divulges novel therapeutic agent for atopic dermatitis

Improvements seen in type 2 diabetes patients given liraglutide

Etravirine demonstrates short-term efficacy in resistant HIV-1 infection

AstraZeneca to acquire MedImmune

Daiichi Sankyo to transfer all Daiichi Fine Chemical shares to Kyowa Hakko

Novel treatment options for HCV infection reported in recent GSK patents

Japanese submission for Glufast in combination with insulin sensitizer

R3 antibody shows efficacy in pancreatic cancer model

Phase IIa biomarker study investigates HF-0220 in mild to moderate Alzheimer's

Pharmion advances oral azacitidine in phase I

Actavis completes acquisition of Abrika

Enrollment completed in phase III study of Cerepro

Recent 3M and Obihiro University patents disclose new antiinfective agents

GGTase I inhibitor and prodrug profiled at AACR annual meeting

In vivo antitumor activity of novel anti-IGF-1R antibody reported by Schering-Plough

Nippon Shinyaku discontinues development of NS-9

FDA accepts Xcytrin NDA for filing

Approvable letter for bazedoxifene in prevention of postmenopausal osteoporosis

Maraviroc recommended for accelerated approval

Roche files Avastin and Xeloda submissions in Europe

New phase I trial studies NPI-0052 in multiple myeloma

Synosia in-licenses rufinamide for anxiety disorders and bipolar mood disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.